Germany's LION bioscience has made a foray into the market for
cheminformatics software with a new package designed to help
pharmaceutical companies identify, select and priortise compounds,
based on data emerging from the medicinal...
Technology holding company Coastal Holdings, has purchased a
significant equity interest in another biotechnology business,
adding to its portfolio of acquisitions and investments in the
biotechnology and nanotechnology fields.
A unique approach to microdosing, providing drug data ahead of
schedule and with improved accuracy, could herald a new era in drug
development in which human ADME data is involved in candidate
selection or deselection.
UK biotechnology company CellFactors has entered administration
following its failure to raise additional funds to further develop
its product Skeletex, a biological matrix derived from human cells
that induces new vascularised bone...
Drug discovery company Ablynx is to enter into a partnership with
Proctor and Gamble Pharmaceuticals. The agreement will make use of
Ablynx's Nanobody platform to develop drug candidates against a
G-protein coupled receptor (GPCR)...
Drug development company Jerini has transferred its peptide
technologies business unit to a wholly owned subsidiary which will
continue to provide and develop peptide-based services and products
for biomedical research.
Moscow, Russia-based Quantum Pharmaceuticals is offering
pharmaceutical and biotechnology companies the opportunity to test
the latest version of its molecular docking software - Quantum 2.0
- at no cost, reports Phil Taylor.
BD Biosciences has acquired Atto Bioscience in a deal worth $25
million (€20m), allowing it to enter the emerging high content cell
analysis market and enhancing its presence in the pharmaceutical
and biotechnology sectors.
In the UK, a groundbreaking partnership between government and
industry has led to the creation of a National Biomanufacturing
Centre, designed to make it easier for fledgling biotechnology
companies to get access to contract manufacturing...
Boehringer Ingelheim has been granted a US patent on a way to
disguise real and placebo tablets in a clinical trial - without
having to resort to placing them in larger capsules which may be
difficult for patients to swallow.